Effects of Functional Oils on Obesity With Mild Cognitive Impairment
Interventional Study of Functional Oils Improving Obesity With Mild Cognitive Impairment Via Regulating White Adipose Tissue Browning
研究概览
详细说明
Obesity is a significant risk factor for the development of cognitive impairment, making precise nutritional interventions a vital strategy for preventing and managing this condition. Based on an established cohort, this randomized controlled trial aims to evaluate the efficacy of substituting regular dietary oil with functional diacylglycerol (DAG) oil in obese patients with MCI.
The study will analyze changes in overall cognitive function, body composition, and dietary quality before and after the 6-month intervention. Furthermore, the study will explore the underlying mechanisms by analyzing biological samples (blood and feces) for alterations in lipid metabolites, gut microbiota composition, inflammatory cytokines, and specific markers of white adipose tissue browning. The findings will help determine the therapeutic potential of DAG oil in regulating lipid metabolism and delaying cognitive decline.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jiaxuan Tao
- 电话号码:+86-15389510275
- 邮箱:taojxxx@163.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100069
- Capital Medical University
-
接触:
- Rong Xiao, PhD
- 电话号码:+86-18611314617
- 邮箱:xiaor22@ccmu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Meets the diagnostic criteria for obesity combined with mild cognitive impairment (MCI) (obesity: BMI ≥28.0 kg/m^2 per the 2022 Chinese Expert Consensus on Obesity Prevention and Treatment; MCI: Montreal Cognitive Assessment [MoCA] score below the education-adjusted cutoff, confirmed by a neurologist)
- Aged 45 to 75 years
- Has not been on a diet or has discontinued dieting for at least 3 months, and has not taken fish oil or similar supplements, or is willing to discontinue such supplements for 3 months prior to the intervention
- Able to accept and consume DAG oil as part of daily diet
- Voluntarily agrees to participate and signs the informed consent form
Exclusion Criteria:
- History of neuropsychiatric disorders such as stroke, epilepsy, or schizophrenia
- Cognitive impairment attributable to depression, thyroid disease, traumatic brain injury, or drug- or alcohol-induced intoxication
- History of cerebrovascular disease, or cognitive decline due to severe impairment of cardiac, hepatic, pulmonary, or renal function
- Use of antibiotics, health products, or nutritional supplements within 2 weeks prior to fecal sample collection; or gastrointestinal symptoms (trauma, inflammation/infection, abdominal pain, diarrhea, or constipation) or vaccination history within the same period
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:RSO Group (Rapeseed Oil)
Participants with obesity and mild cognitive impairment (MCI) will be provided with conventional rapeseed oil (RSO), in which diacylglycerol (DAG) occurs only at the low level naturally present in regular cooking oil (predominantly triacylglycerol), for household use for 6 months.
Dietary guidance based on balanced nutrition principles will be provided.
Compliance, dietary intake, anthropometric, biochemical, and cognitive assessments will be evaluated at baseline and 6 months.
|
A commercially available conventional rapeseed oil for daily household cooking use, containing diacylglycerol (DAG) only at the trace level naturally occurring in regular vegetable oil.
其他名称:
|
|
实验性的:DAG Group (Diacylglycerol Oil)
Participants with obesity and MCI will be provided with rapeseed oil-based diacylglycerol (DAG) oil (DAG content ≥40%), produced from conventional rapeseed oil via lipase-catalyzed enzymatic conversion followed by distillation, deodorization, and decolorization, for household use for 6 months, replacing conventional cooking oil.
Dietary guidance based on balanced nutrition principles will be provided.
Compliance, dietary intake, anthropometric, biochemical, and cognitive assessments will be evaluated at baseline and 6 months.
|
A rapeseed oil-based functional oil produced via lipase-catalyzed enzymatic conversion, with a diacylglycerol content ≥40% (national standard requirement), for daily household cooking use in place of conventional cooking oil.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Cognitive Function
大体时间:Baseline and 6 months
|
Change from baseline in cognitive function assessed by the Montreal Cognitive Assessment (MoCA), which evaluates visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation.
Total score ranges from 0 to 30, with higher scores indicating better cognitive function.
|
Baseline and 6 months
|
|
Change From Baseline in Body Weight
大体时间:Baseline and 6 months
|
Change from baseline in body weight (kg) measured by bioelectrical impedance analysis (InBody body composition analyzer).
|
Baseline and 6 months
|
|
Change From Baseline in Body Fat Percentage
大体时间:Baseline and 6 months
|
Change from baseline in body fat percentage measured by bioelectrical impedance analysis (InBody body composition analyzer).
|
Baseline and 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Visceral Fat Area
大体时间:Baseline and 6 months
|
Change from baseline in visceral fat area measured by bioelectrical impedance analysis (InBody body composition analyzer).
|
Baseline and 6 months
|
|
Change From Baseline in Serum Lipid Concentrations
大体时间:Baseline and 6 months
|
Change from baseline in serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), measured by automated biochemical analyzer.
|
Baseline and 6 months
|
|
Change in Gut Microbiota Composition and Metabolites
大体时间:Baseline and 6 months
|
Change from baseline in fecal gut microbiota composition, alpha/beta diversity, and microbial abundance assessed by 16S ribosomal RNA sequencing, and in microbial metabolites including short-chain fatty acids (e.g., butyrate) assessed by untargeted metabolomics.
|
Baseline and 6 months
|
合作者和调查者
调查人员
- 首席研究员:Rong Xiao, PhD、Capital Medical University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.